This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Here's Why Sarepta Therapeutics (SRPT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Sarepta Therapeutics (SRPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
by Zacks Equity Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bausch (BHC) Q1 Earnings and Revenues Miss, Stock Down
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the first quarter due to incremental macro pressures and a challenging supply chain environment.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Q1 Earnings Beat, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the first quarter. Stock up in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 11.11% and 3.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Sarepta Therapeutics (SRPT) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Sarepta (SRPT) Q4 Earnings Beat, DMD Drugs Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the fourth quarter. The company also raises revenue guidance for the year. Stock down in after-market trading.
Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 5.96% and 6.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More
by Kinjel Shah
Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 96.88% and 3.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Addus HomeCare (ADUS) Matches Q4 Earnings Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 0% and 1.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Sarepta's (SRPT) DMD Gene Therapy Study Data Fails to Impress
by Zacks Equity Research
Sarepta's (SRPT) DMD gene therapy candidate achieves statistically significant improvement in patients but the data fails to meet market expectations. Stock down.